

# Sovan Sarkar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6920254/publications.pdf>

Version: 2024-02-01

63  
papers

20,086  
citations

66234

42  
h-index

118652

62  
g-index

66  
all docs

66  
docs citations

66  
times ranked

31851  
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Mitochondrial Dysfunction by Microplate Reader in hiPSC-Derived Neuronal Cell Models of Neurodegenerative Disorders. <i>Methods in Molecular Biology</i> , 2022, , 1-21.	0.4	2
2	Trehalose limits opportunistic mycobacterial survival during HIV co-infection by reversing HIV-mediated autophagy block. <i>Autophagy</i> , 2021, 17, 476-495.	4.3	39
3	Oxygen Consumption Evaluation: An Important Indicator of Metabolic State, , and Cell Fate Along. <i>Methods in Molecular Biology</i> , 2021, 2240, 207-230.	0.4	2
4	Autophagy Dysfunction as a Phenotypic Readout in hiPSC-Derived Neuronal Cell Models of Neurodegenerative Diseases. <i>Methods in Molecular Biology</i> , 2021, , 103-136.	0.4	4
5	Editorial: Autophagy: From Big Data to Physiological Significance. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 7, 376.	1.8	1
6	Autophagy modulator scoring system: a user-friendly tool for quantitative analysis of methodological integrity of chemical autophagy modulator studies. <i>Autophagy</i> , 2020, 16, 195-202.	4.3	14
7	Human Induced Pluripotent Stem Cell Models of Neurodegenerative Disorders for Studying the Biomedical Implications of Autophagy. <i>Journal of Molecular Biology</i> , 2020, 432, 2754-2798.	2.0	15
8	Autophagy in Neurodegenerative Diseases. <i>Journal of Molecular Biology</i> , 2020, 432, 2445-2448.	2.0	2
9	Autophagy in Rare (NonLysosomal) Neurodegenerative Diseases. <i>Journal of Molecular Biology</i> , 2020, 432, 2735-2753.	2.0	23
10	Biomedical Implications of Autophagy in Macromolecule Storage Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 179.	1.8	22
11	Chemical Screening Approaches Enabling Drug Discovery of Autophagy Modulators for Biomedical Applications in Human Diseases. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 38.	1.8	37
12	In Vitro Screening Platforms for Identifying Autophagy Modulators in Mammalian Cells. <i>Methods in Molecular Biology</i> , 2019, 1880, 389-428.	0.4	14
13	Selective Autophagy and Xenophagy in Infection and Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 147.	1.8	185
14	Discovery of pan autophagy inhibitors through a high-throughput screen highlights macroautophagy as an evolutionarily conserved process across 3 eukaryotic kingdoms. <i>Autophagy</i> , 2017, 13, 1556-1572.	4.3	22
15	Resistance exercise initiates mechanistic target of rapamycin (mTOR) translocation and protein complex co-localisation in human skeletal muscle. <i>Scientific Reports</i> , 2017, 7, 5028.	1.6	86
16	Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. <i>Essays in Biochemistry</i> , 2017, 61, 733-749.	2.1	138
17	PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder. <i>Scientific Reports</i> , 2016, 6, 31750.	1.6	33
18	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701

#	ARTICLE	IF	CITATIONS
19	Autophagy, lipophagy and lysosomal lipid storage disorders. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 269-284.	1.2	189
20	Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. <i>ELife</i> , 2016, 5, .	2.8	147
21	Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E4281-7.	3.3	56
22	Amino acids and autophagy: cross-talk and co-operation to control cellular homeostasis. <i>Amino Acids</i> , 2015, 47, 2065-2088.	1.2	80
23	Direct Lineage Conversion of Adult Mouse Liver Cells and B Lymphocytes to Neural Stem Cells. <i>Stem Cell Reports</i> , 2014, 3, 948-956.	2.3	57
24	Restarting stalled autophagy a potential therapeutic approach for the lipid storage disorder, Niemann-Pick type C1 disease. <i>Autophagy</i> , 2014, 10, 1137-1140.	4.3	18
25	Autophagy researchers. <i>Autophagy</i> , 2014, 10, 552-555.	4.3	0
26	Genetic and Chemical Correction of Cholesterol Accumulation and Impaired Autophagy in Hepatic and Neural Cells Derived from Niemann-Pick Type C Patient-Specific iPS Cells. <i>Stem Cell Reports</i> , 2014, 2, 866-880.	2.3	180
27	The Developmental Potential of iPSCs Is Greatly Influenced by Reprogramming Factor Selection. <i>Cell Stem Cell</i> , 2014, 15, 295-309.	5.2	137
28	Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. <i>Nature Biotechnology</i> , 2013, 31, 653-658.	9.4	660
29	Impaired Autophagy in the Lipid-Storage Disorder Niemann-Pick Type C1 Disease. <i>Cell Reports</i> , 2013, 5, 1302-1315.	2.9	232
30	Chemical screening platforms for autophagy drug discovery to identify therapeutic candidates for Huntington's disease and other neurodegenerative disorders. <i>Drug Discovery Today: Technologies</i> , 2013, 10, e137-e144.	4.0	36
31	Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers. <i>Biochemical Society Transactions</i> , 2013, 41, 1103-1130.	1.6	309
32	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
33	Direct Reprogramming of Fibroblasts into Embryonic Sertoli-like Cells by Defined Factors. <i>Cell Stem Cell</i> , 2012, 11, 373-386.	5.2	147
34	Complex Inhibitory Effects of Nitric Oxide on Autophagy. <i>Molecular Cell</i> , 2011, 43, 19-32.	4.5	340
35	Lysosomal positioning coordinates cellular nutrient responses. <i>Nature Cell Biology</i> , 2011, 13, 453-460.	4.6	726
36	Cystamine Suppresses Polyalanine Toxicity in a Mouse Model of Oculopharyngeal Muscular Dystrophy. <i>Science Translational Medicine</i> , 2010, 2, 34ra40.	5.8	40

#	ARTICLE	IF	CITATIONS
37	Antioxidants can inhibit basal autophagy and enhance neurodegeneration in models of polyglutamine disease. <i>Human Molecular Genetics</i> , 2010, 19, 3413-3429.	1.4	135
38	Deletion of the Huntingtin Polyglutamine Stretch Enhances Neuronal Autophagy and Longevity in Mice. <i>PLoS Genetics</i> , 2010, 6, e1000838.	1.5	140
39	Chemical Inducers of Autophagy That Enhance the Clearance of Mutant Proteins in Neurodegenerative Diseases. <i>Journal of Biological Chemistry</i> , 2010, 285, 11061-11067.	1.6	181
40	Impaired autophagy in Lafora disease. <i>Autophagy</i> , 2010, 6, 991-993.	4.3	30
41	Laforin, the most common protein mutated in Lafora disease, regulates autophagy. <i>Human Molecular Genetics</i> , 2010, 19, 2867-2876.	1.4	170
42	Regulation of Mammalian Autophagy in Physiology and Pathophysiology. <i>Physiological Reviews</i> , 2010, 90, 1383-1435.	13.1	1,557
43	In search of an "autophagometer". <i>Autophagy</i> , 2009, 5, 585-589.	4.3	503
44	Mammalian macroautophagy at a glance. <i>Journal of Cell Science</i> , 2009, 122, 1707-1711.	1.2	163
45	Chapter 5 Autophagic Clearance of Aggregate-Prone Proteins Associated with Neurodegeneration. <i>Methods in Enzymology</i> , 2009, 453, 83-110.	0.4	81
46	Methodological considerations for assessing autophagy modulators: A study with calcium phosphate precipitates. <i>Autophagy</i> , 2009, 5, 307-313.	4.3	67
47	Huntington's disease: degradation of mutant huntingtin by autophagy. <i>FEBS Journal</i> , 2008, 275, 4263-4270.	2.2	177
48	Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. <i>Nature Chemical Biology</i> , 2008, 4, 295-305.	3.9	739
49	Small molecule enhancers of autophagy for neurodegenerative diseases. <i>Molecular BioSystems</i> , 2008, 4, 895.	2.9	146
50	Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. <i>Human Molecular Genetics</i> , 2008, 17, 1097-1108.	1.4	41
51	A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. <i>Human Molecular Genetics</i> , 2008, 17, 170-178.	1.4	312
52	Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. <i>Journal of Cell Science</i> , 2008, 121, 1649-1660.	1.2	284
53	Clearance of Mutant Aggregate-Prone Proteins by Autophagy. <i>Methods in Molecular Biology</i> , 2008, 445, 195-211.	0.4	44
54	Trehalose, a Novel mTOR-independent Autophagy Enhancer, Accelerates the Clearance of Mutant Huntingtin and $\beta$ -Synuclein. <i>Journal of Biological Chemistry</i> , 2007, 282, 5641-5652.	1.6	971

#	ARTICLE	IF	CITATIONS
55	Small Molecule Enhancers of Rapamycin-Induced TOR Inhibition Promote Autophagy, Reduce Toxicity in Huntington's Disease Models and Enhance Killing of Mycobacteria by Macrophages. <i>Autophagy</i> , 2007, 3, 620-622.	4.3	150
56	Hydrophilic protein associated with desiccation tolerance exhibits broad protein stabilization function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18073-18078.	3.3	276
57	The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias. <i>BMC Biochemistry</i> , 2007, 8, S2.	4.4	47
58	Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. <i>Nature Chemical Biology</i> , 2007, 3, 331-338.	3.9	572
59	Inositol and IP3 Levels Regulate Autophagy's Biology and Therapeutic Speculations. <i>Autophagy</i> , 2006, 2, 132-134.	4.3	151
60	Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. <i>Human Molecular Genetics</i> , 2006, 15, 23-31.	1.4	191
61	Aggregate-Prone Proteins Are Cleared from the Cytosol by Autophagy: Therapeutic Implications. <i>Current Topics in Developmental Biology</i> , 2006, 76, 89-101.	1.0	262
62	Lithium induces autophagy by inhibiting inositol monophosphatase. <i>Journal of Cell Biology</i> , 2005, 170, 1101-1111.	2.3	868
63	The roles of the ubiquitin-proteasome and autophagy-lysosome pathways in Huntington's disease and related conditions. <i>Clinical Neuroscience Research</i> , 2003, 3, 141-148.	0.8	10